Effects pf Biological Response Modifies on the Prevalence pf Autoantibodies to Vascular Injury in Agroup of Iraqi Patients with Autoimmune Disease
Keywords:
autoantibodies, vascular injury, Iraqi patients , autoimmune diseaseAbstract
Background;. biological disease modifiers mainly those targeting tumor necrosis factor (Etanercept), (Infliximab), together with (Adalimumab) are currently an important part of the treatment plan for seropositive poly-articular arthropathy. Since these drugs greatly affect the course of the disease, they alter the treatment of this condition and significantly slow down X-ray progression of the aforementioned condition. Some biologics are designed to precisely suppress tumor necrosis factor (TNF), a key regulator of joint pain and damage. Tumor necrosis factor is a predominant inflammatory interleukin which synchronizes the release of other soluble mediators [1]. Purpose: to assess the changes in P-ANCA an indicator of vascular injury after treatment with the biologic Etanercept (anti-TNFα) in patients with refractory seropositive polyarticular arthropathy. Methods: patients with refractory and classically unrelieved seropositive poly-articular arthropathy received a biological modulator (Etanercept) for 3 months. Participants' sera were collected and examined consecutively for P-ANCA at baseline as well as post-dosing. Statistical analysis was performed using the SPSS 10. Results: after 3 months, there was a significant decrease in serum anti-lactoferrin level of nearly 97%, and a concomitant increase of anti-lysozyme, with an increase of 551.6%. However, other autoantibodies are elevated, non-importantly. Conclusion: Etanercept had variable effects on P-ANCA in patients with refractory seropositive poly arthropathy after 3 months of therapy.
Downloads
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
